Publications by authors named "G A Khodarahmi"

In this study novel triazine-tyrosine hybrids containing thiazole or pyridine fragments were introduced as anti- Multiple Sclerosis agents. The compounds were designed according to the structure of the Sphingosine-1-phosphate receptor subtype 1 (S1P1) modulator, fingolimode. At first, docking studies was performed using crystal structures of S1P1 and Sphingosine-1-phosphate receptor subtype 3 (S1P3) to theoretically identify the selectivity of the compounds towards the S1P1 isoform.

View Article and Find Full Text PDF

Heat shock proteins (Hsp) and FoxM1 have significant roles in carcinogenesis. According to their relative molecular weight, Hsps are divided into Hsp110, Hsp90, Hsp70, Hsp60, Hsp40, and small Hsps. Hsp70 can play essential functions in cancer initiation and is overexpressed in several human cancers.

View Article and Find Full Text PDF

Background And Purpose: FoxM1 and Hsp70 proteins are highly expressed in many cancers. Thus, their inhibition serves as Bonafede targets in cancer treatment.

Experimental Approach: FDI-6, an inhibitor of FoxM1, was selected as a template, and based on its structure, a new library from the ZINC database was obtained.

View Article and Find Full Text PDF

To design and develop novel antimicrobial agents, a series of phthalimide-triazine-based derivatives (6a-6e) were synthesized, characterized and evaluated for their potential antibacterial activities. The compounds were prepared through reaction of 6-phenyl-1,3,5-triazine-2,4-diamine with phthalimide moiety containing aliphatic amino acid. Structural analysis of the synthesized compounds was carried out by various characterization techniques such as FT-IR, H and C-NMR and mass spectroscopy.

View Article and Find Full Text PDF
Article Synopsis
  • A study investigated S1P1 receptor modulators to slow down multiple sclerosis (MS) by reducing lymphocyte cells in a rat model.
  • Molecular docking compared the binding of these compounds to S1P1 with that of the drug fingolimod, leading to the synthesis of various compounds.
  • Results showed that the best compound had a lower binding energy than fingolimod and effectively reduced lymphocyte levels, indicating potential for future MS treatments.
View Article and Find Full Text PDF